Qingdao Baheal Medical INC. (301015) - Total Liabilities

Latest as of March 2026: CN¥5.67 Billion CNY ≈ $829.59 Million USD

Based on the latest financial reports, Qingdao Baheal Medical INC. (301015) has total liabilities worth CN¥5.67 Billion CNY (≈ $829.59 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Qingdao Baheal Medical INC. (301015) equity growth momentum to track the company's year-over-year net asset growth rate.

Qingdao Baheal Medical INC. - Total Liabilities Trend (2018–2025)

This chart illustrates how Qingdao Baheal Medical INC.'s total liabilities have evolved over time, based on quarterly financial data. See Qingdao Baheal Medical INC. (301015) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Qingdao Baheal Medical INC. Competitors by Total Liabilities

The table below lists competitors of Qingdao Baheal Medical INC. ranked by their total liabilities.

Company Country Total Liabilities
Array Digital Infrastructure, Inc.
NYSE:AD
USA $2.10 Billion
McGraw Hill, Inc.
NYSE:MH
USA $4.87 Billion
Foryou Corp
SHE:002906
China CN¥7.56 Billion
Mobileye Global Inc. Class A Common Stock
NASDAQ:MBLY
USA $571.00 Million
Flywire Corp
NASDAQ:FLYW
USA $310.15 Million
Stanmore Resources Ltd
AU:SMR
Australia AU$2.06 Billion
ArcSoft Corp Ltd
SHG:688088
China CN¥364.94 Million
Xiamen ITG Group Corp Ltd
SHG:600755
China CN¥102.92 Billion

Liability Composition Analysis (2018–2025)

This chart breaks down Qingdao Baheal Medical INC.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Qingdao Baheal Medical INC. (301015) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.43 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.19 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.66 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Qingdao Baheal Medical INC.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Qingdao Baheal Medical INC. (2018–2025)

The table below shows the annual total liabilities of Qingdao Baheal Medical INC. from 2018 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥5.37 Billion
≈ $785.86 Million
+19.13%
2024-12-31 CN¥4.51 Billion
≈ $659.65 Million
+36.69%
2023-12-31 CN¥3.30 Billion
≈ $482.61 Million
+16.30%
2022-12-31 CN¥2.84 Billion
≈ $414.97 Million
+16.76%
2021-12-31 CN¥2.43 Billion
≈ $355.41 Million
-4.83%
2020-12-31 CN¥2.55 Billion
≈ $373.44 Million
+20.12%
2019-12-31 CN¥2.12 Billion
≈ $310.90 Million
+37.78%
2018-12-31 CN¥1.54 Billion
≈ $225.65 Million
--

About Qingdao Baheal Medical INC.

SHE:301015 China Medical Distribution
Market Cap
$1.82 Billion
CN¥12.47 Billion CNY
Market Cap Rank
#6407 Global
#1256 in China
Share Price
CN¥23.72
Change (1 day)
+0.89%
52-Week Range
CN¥19.06 - CN¥31.35
All Time High
CN¥51.67
About

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Ha… Read more